search
Back to results

Hemodynamics Response to Upper Airway Obstruction in Marfan Syndrome (MSB)

Primary Purpose

Sleep-disordered Breathing, Snoring

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CPAP
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep-disordered Breathing

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

People with Marfan syndrome.

  • Age β‰₯ 18yrs
  • Able and willing to provide informed consent
  • Willing to sleep connected to research apparatus

Exclusion Criteria:

  • Unstable cardiovascular disease (CHF, myocardial infarction or revascularization procedures, and unstable arrhythmias)
  • Uncontrolled hypertension (BP > 190/110)
  • Underlying obstructive or other intrinsic lung disease
  • Renal failure on dialysis
  • Cirrhosis
  • Pregnancy

Sites / Locations

  • Johns Hopkins University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Baseline Sleep Study

CPAP Sleep Study

Arm Description

Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.

Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.

Outcomes

Primary Outcome Measures

Pleural Pressure (Pes)
Pleural pressure (Pes) in mmHg monitored using an esophageal catheter.
Mean Arterial Blood Pressure (MAP)
Continuous blood pressure monitored using a non-invasive finger cuff. Data captured in mmHg.

Secondary Outcome Measures

Augmentation Index (AI)
The AI (measured as "percentage of pulse pressure") was assessed in the morning after both Baseline and CPAP studies. It is a measure of arterial stiffness that represents the degree of and can range from -10% to +10% in healthy individuals, with values generally higher in females and increases with age.
Reactive Hyperemia Index (RHI)
The RHI is a measure of endothelial function that was measured in the morning after both Baseline and CPAP studies. It is unitless and scored on a range of 1 to 3 in healthy individuals with lower values indicating poor endothelial function.

Full Information

First Posted
June 11, 2019
Last Updated
December 2, 2020
Sponsor
Johns Hopkins University
Collaborators
The Marfan Foundation, National Institutes of Health (NIH)
search

1. Study Identification

Unique Protocol Identification Number
NCT03985657
Brief Title
Hemodynamics Response to Upper Airway Obstruction in Marfan Syndrome
Acronym
MSB
Official Title
Sleep Disordered Breathing in Marfan Syndrome: Susceptibility and Hemodynamics
Study Type
Interventional

2. Study Status

Record Verification Date
December 2020
Overall Recruitment Status
Completed
Study Start Date
June 6, 2018 (Actual)
Primary Completion Date
December 6, 2019 (Actual)
Study Completion Date
December 6, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
The Marfan Foundation, National Institutes of Health (NIH)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
Upper airway obstruction (UAO) is an unrecognized source of hemodynamic stress that may contribute to aortic adverse events in persons with Marfan Syndrome (MFS). UAO occurs during snoring and sleep apnea and is characterized by repetitive partial or complete obstruction of the upper airway during sleep. These obstructive breathing events lead to intermittent surges in blood pressure (BP) REF and large decreases in pleural pressure (Pes), thereby increasing the trans-mural aortic pressure (TMP) and imposing mechanical stress on the aorta during sleep. Although UAO is known to increase mechanical stress on the aorta, the magnitude of the increase is not known for persons with MFS. In this project, therefore, the investigators will also examine the changes in Pes and BP responses in periods of obstructed breathing and compare the diurnal markers or vascular stress between Baseline and CPAP studies in MFS persons.
Detailed Description
Research Objective/Significance: Specific Aim 1a: To quantify the Pes and BP during periods with and without UAO during sleep in persons with MFS. Specific Aim 1b: To examine the effect of CPAP treatment of UAO on Pes and BP in MFS persons. Specific Aim 2: To examine the effect of CPAP treatment of UAO on daytime markers of hemodynamic stress (augmentation index, reactive hyperemia index) in MFS persons. Primary Outcomes: Overnight measure of hemodynamic stress (blood pressure, pleural pressure swings) Secondary Outcomes: Changes in diurnal markers of hemodynamic stress (augmentation index, reactive hyperemia index)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep-disordered Breathing, Snoring

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Participants will be assigned to a Baseline polysomnography and CPAP polysomnography in a randomized fashion. Participants will then be switched to the second polysomnography within 14 days of the first. The baseline polysomnography represents the exposure to sleep disordered breathing and the CPAP polysomnography represents the relief of the exposure. Markers of hemodynamic stress will be assessed in the morning after both studies.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Baseline Sleep Study
Arm Type
Active Comparator
Arm Description
Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.
Arm Title
CPAP Sleep Study
Arm Type
Experimental
Arm Description
Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.
Intervention Type
Device
Intervention Name(s)
CPAP
Intervention Description
Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
Primary Outcome Measure Information:
Title
Pleural Pressure (Pes)
Description
Pleural pressure (Pes) in mmHg monitored using an esophageal catheter.
Time Frame
Overnight on both CPAP and No CPAP nights
Title
Mean Arterial Blood Pressure (MAP)
Description
Continuous blood pressure monitored using a non-invasive finger cuff. Data captured in mmHg.
Time Frame
Overnight on both Baseline and CPAP studies
Secondary Outcome Measure Information:
Title
Augmentation Index (AI)
Description
The AI (measured as "percentage of pulse pressure") was assessed in the morning after both Baseline and CPAP studies. It is a measure of arterial stiffness that represents the degree of and can range from -10% to +10% in healthy individuals, with values generally higher in females and increases with age.
Time Frame
15 minutes in the morning post Baseline and CPAP studies
Title
Reactive Hyperemia Index (RHI)
Description
The RHI is a measure of endothelial function that was measured in the morning after both Baseline and CPAP studies. It is unitless and scored on a range of 1 to 3 in healthy individuals with lower values indicating poor endothelial function.
Time Frame
15 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: People with Marfan syndrome. Age β‰₯ 18yrs Able and willing to provide informed consent Willing to sleep connected to research apparatus Exclusion Criteria: Unstable cardiovascular disease (CHF, myocardial infarction or revascularization procedures, and unstable arrhythmias) Uncontrolled hypertension (BP > 190/110) Underlying obstructive or other intrinsic lung disease Renal failure on dialysis Cirrhosis Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mudiaga Sowho
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Hemodynamics Response to Upper Airway Obstruction in Marfan Syndrome

We'll reach out to this number within 24 hrs